Sign in / Join Now
ETFs & Funds
The science behind Vascepa hasn't changed. $
will be vindicated long term, but that's no relief to those who've sustained big losses.
Add a reply...
Latest StockTalks »
people get AMRN breaking news and analysis by email alert.
Get email alerts on AMRN »
Amarin Corporation PLC
Get latest price
From other sites
Amarin Corporation (AMRN) Looks Good: Stock Adds 6.1% in Session
at Zacks.com (Tue, 8:00AM)
Amarin's REDUCE-IT Cardiovascular Outcomes Study Of Vascepa To Continue As Planned At Recommendation Of Independent Data Monitoring Committee
at TheStreet (Sep 12, 2016)
Zacks.com featured highlights: Amarin, Compugen, Raptor Pharmaceuticals, ArcelorMittal and Hovnanian Enterprises
at Zacks.com (Sep 7, 2016)
Amarin To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
at TheStreet (Sep 7, 2016)
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
at Zacks.com (Sep 1, 2016)